MARKET

LCTX

LCTX

Lineage Cell The
AMEX
1.700
+0.020
+1.19%
After Hours: 1.720 +0.02 +1.18% 19:55 02/06 EST
OPEN
1.700
PREV CLOSE
1.680
HIGH
1.740
LOW
1.655
VOLUME
1.08M
TURNOVER
--
52 WEEK HIGH
2.090
52 WEEK LOW
0.3651
MARKET CAP
391.56M
P/E (TTM)
-5.7549
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LCTX last week (0126-0130)?
Weekly Report · 5d ago
Weekly Report: what happened at LCTX last week (0119-0123)?
Weekly Report · 01/26 09:46
Weekly Report: what happened at LCTX last week (0112-0116)?
Weekly Report · 01/19 09:49
Weekly Report: what happened at LCTX last week (0105-0109)?
Weekly Report · 01/12 09:48
De-Risked Cell Therapy Platform and Roche Partnership Momentum Underpin Buy Rating on Lineage (LCTX)
TipRanks · 01/06 16:46
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
Barchart · 01/06 07:00
Weekly Report: what happened at LCTX last week (1229-0102)?
Weekly Report · 01/05 09:45
Weekly Report: what happened at LCTX last week (1222-1226)?
Weekly Report · 12/29/2025 09:44
More
About LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological and ophthalmic conditions. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.

Webull offers Lineage Cell Therapeutics Inc stock information, including AMEX: LCTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LCTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LCTX stock methods without spending real money on the virtual paper trading platform.